Celgene invests in VentiRx cancer immunotherapies

10/3/2012 | Xconomy

Celgene will pay VentiRx $35 million in a collaboration to develop a drug that stimulates the immune system to fight cancer. The deal gives Celgene an option to acquire VentiRx and gives other investors a predictable return if the drug is successful. "Celgene and VentiRx are forging ahead with the kind of long-term, expensive clinical trials that will be needed to prove the value of the product to physicians, regulators, and insurers," Luke Timmerman writes.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA